Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.21 USD

38.21
1,262,631

-0.41 (-1.06%)

Updated Aug 8, 2025 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sheraz Mian headshot

Top Research Reports for Roche, Exxon Mobil & Honeywell

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Exxon Mobil Corporation (XOM), and Honeywell International Inc. (HON).

Zacks Equity Research

Bristol Myers (BMY) UC Candidate Fails in Phase II Study

by Zacks Equity Research

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

Neena Mishra headshot

Should You Invest in Travel & Tourism ETFs Now?

by Neena Mishra

Travel stocks could benefit from pent-up demand as we return to normal

Zacks Equity Research

Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy

by Zacks Equity Research

Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.

Zacks Equity Research

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

by Zacks Equity Research

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

Zacks Equity Research

Regeneron (REGN) Reports Positive Data on Antibody Cocktail

by Zacks Equity Research

Regeneron's (REGN) phase III study assessing REGEN-COV in patients hospitalized with COVID-19 meets its primary goal.

Zacks Equity Research

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

Zacks Equity Research

Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study

by Zacks Equity Research

Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.

Zacks Equity Research

Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal

by Zacks Equity Research

Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.

Zacks Equity Research

Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation

by Zacks Equity Research

Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.

Zacks Equity Research

Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

by Zacks Equity Research

Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.

Zacks Equity Research

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

Zacks Equity Research

Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review

by Zacks Equity Research

Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.

Zacks Equity Research

Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

by Zacks Equity Research

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

Zacks Equity Research

Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.

Zacks Equity Research

Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer

by Zacks Equity Research

Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

Zacks Equity Research

Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

Zacks Equity Research

Regeneron, Lilly Get New COVID Drug Deals From Government

by Zacks Equity Research

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.

Zacks Equity Research

OPKO Health (OPK) Forms JV, Establishes Presence in China

by Zacks Equity Research

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

Zacks Equity Research

Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

by Zacks Equity Research

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

Zacks Equity Research

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

by Zacks Equity Research

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

Zacks Equity Research

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

by Zacks Equity Research

Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca

Zacks Equity Research

Will Regeneron's (REGN) Antibody Cocktail Fuel Further Growth?

by Zacks Equity Research

Regeneron's (REGN) performance in the year has gained from higher demand for its antibody cocktail - REGEN-COV.

Zacks Equity Research

Roche's (RHHBY) Sparks Set to Develop Gene Therapy for HD

by Zacks Equity Research

Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.